Unknown

Dataset Information

0

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.


ABSTRACT: PURPOSE:Vascular endothelial growth factor receptor (VEGFR2) directed therapies result in a modest survival benefit for patients with advanced esophageal and gastroesophageal (GE) junction cancer. Platelet-derived growth factor receptor (PDGFR) may contribute to escape from VEGFR2 inhibition. We evaluated the efficacy of sorafenib, a broad spectrum tyrosine kinase inhibitor targeting VEGFR2 and PDGFR as well as RET and RAF1, in patients with metastatic chemotherapy refractory esophageal and GE junction cancer. PATIENTS AND METHODS:This phase II trial of sorafenib 400 mg twice daily enrolled chemotherapy refractory patients with metastatic esophageal and GE junction cancer with primary endpoint of progression-free survival (PFS) rate at two months. Secondary endpoints included overall survival, objective response rate and toxicity. RESULTS:Among 34 patients, 8 week Kaplan-Meier estimated PFS was 61% (90%CI 45 to 73%). Median PFS is 3.6 months (95% CI 1.8 to 3.9 months), with median overall survival OS 9.7 months (95% CI 5.9 to 11.6 months). Grade 3 toxicities were uncommon and included hand foot skin reaction, rash, dehydration and fatigue. One patient (3%) with ongoing complete response and remains on trial for over 5 years. Whole exome sequencing of this tumor revealed mutations in many cancer-associated genes including ARID1A, PIK3CA, and TP53, and focal amplifications of HMGA2 and MET. CONCLUSION:Sorafenib therapy results in disease stabilization and encouraging PFS in patients with refractory esophageal and GE junction cancer. TRIAL REGISTRATION:ClinicalTrials.gov NCT00917462.

SUBMITTER: Janjigian YY 

PROVIDER: S-EPMC4537304 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

Janjigian Yelena Y YY   Vakiani Efsevia E   Ku Geoffrey Y GY   Herrera Jessica M JM   Tang Laura H LH   Bouvier Nancy N   Viale Agnès A   Socci Nicholas D ND   Capanu Marinela M   Berger Michael M   Ilson David H DH  

PloS one 20150814 8


<h4>Purpose</h4>Vascular endothelial growth factor receptor (VEGFR2) directed therapies result in a modest survival benefit for patients with advanced esophageal and gastroesophageal (GE) junction cancer. Platelet-derived growth factor receptor (PDGFR) may contribute to escape from VEGFR2 inhibition. We evaluated the efficacy of sorafenib, a broad spectrum tyrosine kinase inhibitor targeting VEGFR2 and PDGFR as well as RET and RAF1, in patients with metastatic chemotherapy refractory esophageal  ...[more]

Similar Datasets

| S-EPMC5019745 | biostudies-literature
| S-EPMC6527138 | biostudies-literature
| S-EPMC10485278 | biostudies-literature
| S-EPMC2903332 | biostudies-literature
| S-EPMC5491642 | biostudies-literature
| S-EPMC5167316 | biostudies-literature
| S-EPMC10543966 | biostudies-literature
| S-EPMC10553121 | biostudies-literature
| S-EPMC8176978 | biostudies-literature
| S-EPMC5342387 | biostudies-literature